Fiscal year ends DecLast earnings: Apr 21, 2026Est. next earnings: Jul 21, 2026
Latest Score
9.0/ 10
+2.0vs prior
4-Period Change
+2.0
vs Q1 '25
Challenge RatePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
0%
All quarters
9.0out of 10Positive
Sentiment · FY2026 Q1
Q4 '24Q1 '26
Top Analysts & Firms
Most Active Analysts
Analyst
Firm
Questions
ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
Base7Base 7GAAP revenue YoY +9.16% → base 7. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.+Transcript0
Transcript 0GAAP revenue 9.16% (base 7, in 8-14% band). Organic revenue 9% with M&A contributing approximately 0.2% (9.2% total minus 9% organic). M&A well below 10% threshold. No Tier 1 or Tier 2 distortion applies. tx = 0.
+
EPS+1EPS +1GAAP EPS YoY +15.46% vs revenue YoY +9.16%, GAAP spread +6.30 percentage points (outside +5 percentage points → GAAP-only answer = +1). operating income spread: operating income YoY +15.32% vs revenue YoY +9.16%, spread +6.16 percentage points (outside +5 percentage points, same direction as GAAP). Both outside, same direction → GAAP adjustment stands. EPS adjustment = +1.
+
Guidance+1Guidance +1Decision gate: Is this the first time FY2026 guidance was introduced? NO — FY2026 guidance introduced in FY2025-Q4. This is a revision. Revenue midpoint: prior $11.76B → new $11.84B. Change = (11.84 - 11.76) / 11.76 = 0.68%. EPS midpoint: prior $10.60 → new $10.73. Change = (10.73 - 10.60) / 10.60 = 1.23%. EPS change larger (1.23%) → use that. Raise <3%.
=
Final9
How this score was built
Base7Base 7GAAP revenue YoY +9.16% → base 7. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.+Transcript0Transcript 0GAAP revenue 9.16% (base 7, in 8-14% band). Organic revenue 9% with M&A contributing approximately 0.2% (9.2% total minus 9% organic). M&A well below 10% threshold. No Tier 1 or Tier 2 distortion applies. tx = 0.+EPS+1EPS +1GAAP EPS YoY +15.46% vs revenue YoY +9.16%, GAAP spread +6.30 percentage points (outside +5 percentage points → GAAP-only answer = +1). operating income spread: operating income YoY +15.32% vs revenue YoY +9.16%, spread +6.16 percentage points (outside +5 percentage points, same direction as GAAP). Both outside, same direction → GAAP adjustment stands. EPS adjustment = +1.+Guidance+1Guidance +1Decision gate: Is this the first time FY2026 guidance was introduced? NO — FY2026 guidance introduced in FY2025-Q4. This is a revision. Revenue midpoint: prior $11.76B → new $11.84B. Change = (11.84 - 11.76) / 11.76 = 0.68%. EPS midpoint: prior $10.60 → new $10.73. Change = (10.73 - 10.60) / 10.60 = 1.23%. EPS change larger (1.23%) → use that. Raise <3%.=Final9
Macro Signals
→Regulation Policy↑Consumer Spending
Quest posted 9.2% revenue growth with 9% organic acceleration and adjusted EPS of $2.50 (up 15%), with operating margin expanding to 15.4%. FY2026 guidance was raised to $11.78-11.9 billion revenue and $10.63-10.83 EPS on strong Q1 momentum. AD-Detect Alzheimer's testing more than doubled, Fresenius and Corewell contributed to 7% organic volume, and AI-driven automation was enhancing productivity and patient engagement.
Key Themes8
positive📊 company
Strong Organic-Driven Revenue Acceleration
Consolidated revenues up 9.2% with 9% organic growth. Almost entirely organic with only minimal M&A carryover. Organic volume up 10.8%, or 3.8% excluding Fresenius and Corewell.
Revenue GrowthDemand
positive📊 company
Fresenius And Corewell Contributing 7% Organic Volume
Fresenius Medical Care and Corewell Health contributed approximately 7% to organic volume growth. Corewell implementation proceeding smoothly with joint venture lab planned for 2027.
Revenue GrowthGeographic Expansion
positive📊 company
AD-Detect Alzheimer'S Testing More Than Doubled
Brain health AD-Detect blood test volumes more than doubled year-over-year in Q1. Proprietary algorithm combining multiple biomarkers achieves 90%+ sensitivity and specificity. Physicians increasingly using blood tests in lieu of PET/CT imaging.
Innovation & R&DProduct LaunchDemand
positive📊 company
Consumer Channel Broad-Based Momentum
Significant revenue growth from both questhealth.com and consumer health collaborations. Robust double-digit customer repeat rates. Elite Health Profile and autoimmune tests driving demand. Preferred lab engine for top consumer brands.
Subscriber GrowthDemandRevenue Growth
positive📊 company
AI And Automation Driving Productivity And Patient Engagement
Customer service agent productivity up 40% using AI email triage. Quest AI Companion powered by Google Gemini engaged approximately 350,000 times on MyQuest app. Project Nova on track for fall 2027 first wave.
Cloud & AICapex Investment
positive📊 company
Guidance Raised On Strong Q1 Momentum
FY2026 guidance raised: revenue $11.78 billion to $11.9 billion, adjusted EPS $10.63-$10.83. Operating margin expected to expand versus prior year.
Guidance ReliabilityRevenue Growth
mixed🏢 sector
PAMA Survey Approaching With RESULTS Act Momentum
PAMA data collection opens May 1 through end of July. CMS requiring labs with $25K+ Medicare revenue to submit. Over 80 RESULTS Act cosponsors. If all labs report, Quest believes rates should increase given its sub-20% Medicare market share.
Regulation PolicyPricing
positive📊 company
Haystack MRD And Oncology Pipeline Advancing
Research collaboration with City of Hope across 14 U.S. sites for solid tumor cancers. PLA codes priced at $3,900 baseline and $800 monitoring. MolDX technical assessment submitted for Medicare Advantage. Guardant Shield partnership launched mid-quarter.
I'd love you to put that in perspective and maybe talk through what you see happening in the government in terms of various fraud, waste and abuse initiatives
Charles River's first full quarter under new CEO Birgit Girshick delivered Q1 results in line with lowered expectations, with $996M in revenue declining 1